Skip to main content

Alphatec Holdings Mourns Loss of Board Member

Tipranks - Sat Nov 8, 2025

Meet Your ETF AI Analyst

An announcement from Alphatec Holdings ( (ATEC) ) is now available.

On November 7, 2025, Alphatec Holdings announced the passing of Jeffrey P. Rydin, a respected member of its Board of Directors, who died on November 3, 2025, after a lengthy illness. Rydin, who joined ATEC in 2016, played a pivotal role in transforming the company’s sales channel and was instrumental in its turnaround efforts. His contributions were highly valued by the company, and his passing is deeply mourned by the ATEC community, highlighting his significant impact on the company’s culture and momentum.

The most recent analyst rating on (ATEC) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Alphatec Holdings stock, see the ATEC Stock Forecast page.

Spark’s Take on ATEC Stock

According to Spark, TipRanks’ AI Analyst, ATEC is a Neutral.

The overall stock score is driven by strong earnings call results, highlighting significant revenue growth and positive guidance. However, financial performance concerns, including profitability and cash flow challenges, weigh down the score. Technical analysis shows bullish momentum, but overbought conditions could pose short-term risks. Valuation remains a concern due to the negative P/E ratio.

To see Spark’s full report on ATEC stock, click here.

More about Alphatec Holdings

Alphatec Holdings, Inc. (ATEC) is a medical device company focused on revolutionizing spine surgery through clinical distinction. The company operates through its subsidiaries, Alphatec Spine, Inc., EOS imaging S.A.S., and SafeOp Surgical, Inc., and aims to set the standard in spine surgery with its innovative approaches and the AlphaInformatiX Platform.

Average Trading Volume: 2,221,948

Technical Sentiment Signal: Buy

Current Market Cap: $2.93B

For a thorough assessment of ATEC stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.